De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Sunzen Biotech Berhad Beheer

Beheer criteriumcontroles 2/4

De CEO Sunzen Biotech Berhad's is Yek Teo, benoemd in Jun2020, heeft een ambtstermijn van 4.33 jaar. bezit rechtstreeks 19.18% van de aandelen van het bedrijf, ter waarde MYR 47.15M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.9 jaar en 4.2 jaar.

Belangrijke informatie

Yek Teo

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	4.3yrs
Eigendom CEO	19.1%
Management gemiddelde ambtstermijn	2.9yrs
Gemiddelde ambtstermijn bestuur	4.2yrs

Recente managementupdates

Recent updates

Sunzen Biotech Berhad's (KLSE:SUNZEN) Returns On Capital Are Heading Higher

Aug 06

If EPS Growth Is Important To You, Sunzen Biotech Berhad (KLSE:SUNZEN) Presents An Opportunity

May 25

Optimistic Investors Push Sunzen Biotech Berhad (KLSE:SUNZEN) Shares Up 27% But Growth Is Lacking

May 24

Sunzen Biotech Berhad (KLSE:SUNZEN) Is Doing The Right Things To Multiply Its Share Price

Apr 22

Sunzen Biotech Berhad (KLSE:SUNZEN) Shareholders Will Want The ROCE Trajectory To Continue

Jan 19

What Sunzen Biotech Berhad's (KLSE:SUNZEN) 27% Share Price Gain Is Not Telling You

Nov 16

Health Check: How Prudently Does Sunzen Biotech Berhad (KLSE:SUNZEN) Use Debt?

Mar 26

Is Sunzen Biotech Berhad (KLSE:SUNZEN) Weighed On By Its Debt Load?

Dec 10

Analyse CEO-vergoeding

Hoe is Yek Teo's beloning veranderd ten opzichte van Sunzen Biotech Berhad's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	RM 6m
Dec 31 2023	n/a	n/a	RM 7m
Sep 30 2023	n/a	n/a	RM 5m
Jun 30 2023	n/a	n/a	RM 4m
Mar 31 2023	n/a	n/a	RM 4m
Dec 31 2022	RM 214k	RM 175k	RM 4m
Sep 30 2022	n/a	n/a	RM 3m
Jun 30 2022	n/a	n/a	RM 2m
Mar 31 2022	n/a	n/a	RM 2m
Dec 31 2021	RM 148k	RM 120k	RM 680k
Sep 30 2021	n/a	n/a	-RM 9m
Jun 30 2021	n/a	n/a	-RM 9m
Mar 31 2021	n/a	n/a	-RM 11m
Dec 31 2020	RM 74k	RM 65k	-RM 13m

Compensatie versus markt: Er zijn onvoldoende gegevens om vast te stellen of de totale vergoeding van Yek redelijk is in vergelijking met bedrijven van vergelijkbare omvang in de MY markt.

Compensatie versus inkomsten: De vergoeding van Yek is het afgelopen jaar met meer dan 20% gestegen.

CEO

Yek Teo (40 yo)

4.3yrs

Tenure

RM 213,802

Compensatie

Mr. Yek Ming Teo serves as Executive Director at Sunzen Biotech Berhad since June 16, 2020 and served as its Group Managing Director cum Group Chief Executive Officer since June 16, 2020 until February 25,...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Chee Ching	Executive Chairman	4.2yrs	RM 77.88k	0.58% MYR 1.4m
Yek Teo	Group MD & Executive Director	4.3yrs	RM 213.80k	19.15% MYR 46.5m
Tong Phang	Chief Financial Officer	no data	geen gegevens	geen gegevens
Wee Lim	Sales & Marketing Director	no data	geen gegevens	geen gegevens
Mee Teo	Company Secretary	9.9yrs	geen gegevens	geen gegevens
Weng Cheng	Joint Company Secretary	less than a year	geen gegevens	geen gegevens

2.9yrs

Gemiddelde duur

47.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van SUNZEN wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.9 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Chee Ching	Executive Chairman	4.2yrs	RM 77.88k	0.58% MYR 1.4m
Yek Teo	Group MD & Executive Director	4.3yrs	RM 213.80k	19.15% MYR 46.5m
Yew Lee	Non Independent Non-Executive Director	4.2yrs	RM 69.20k	geen gegevens
Kien Khoo	Independent Non-Executive Director	10.3yrs	RM 28.40k	geen gegevens
Musa Bin Hassan	Senior Independent Non-Executive Director	10.3yrs	RM 62.60k	geen gegevens
Long Poo	Independent & Non-Executive Director	1.6yrs	geen gegevens	0.012% MYR 28.2k
Aida Binti Abdullah	Independent & Non Executive Director	less than a year	geen gegevens	geen gegevens

4.2yrs

Gemiddelde duur

49yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SUNZEN wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.2 jaar).

Sunzen Biotech Berhad Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Sunzen Biotech Berhad Announces Appointment of Aida Lim Binti Abdullah as Independent and Non Executive Member of Nomination Committee

Sunzen Biotech Berhad Announces Resignation of Zeenath Begum Binti Mohamed Mastan as Joint Company Secretary

Sunzen Biotech Berhad Announces Appointment of Lee Yew Weng as Non Independent and Non Executive Member of Remuneration Committee

Sunzen Biotech Berhad Appoints Lee Yew Weng as Non Independent and Non Executive Member of Nomination Committee

Sunzen Biotech Berhad Announces the Resignation of Dr. Fong Chan Seng as Independent and Non Executive Director, Member of Remuneration Committee, Chairman of Nomination Committee

Sunzen Biotech Berhad Announces Redesignation of Ching Chee Pun as Executive Chairman

Recent updates

Sunzen Biotech Berhad (KLSE:SUNZEN) acquired additional 30% stake in Ecolite Biotech Manufacturing Sdn Bhd from group of sellers for MYR 15 million.

Sunzen Biotech Berhad's (KLSE:SUNZEN) Returns On Capital Are Heading Higher

Now 22% undervalued

If EPS Growth Is Important To You, Sunzen Biotech Berhad (KLSE:SUNZEN) Presents An Opportunity

Optimistic Investors Push Sunzen Biotech Berhad (KLSE:SUNZEN) Shares Up 27% But Growth Is Lacking

Sunzen Biotech Berhad (KLSE:SUNZEN) Is Doing The Right Things To Multiply Its Share Price

Sunzen Biotech Berhad (KLSE:SUNZEN) Shareholders Will Want The ROCE Trajectory To Continue

Sunzen Biotech Berhad Announces Appointment of Aida Lim Binti Abdullah as Independent and Non Executive Member of Nomination Committee

Third quarter 2023 earnings released: EPS: RM0.002 (vs RM0.001 in 3Q 2022)

Sunzen Biotech Berhad Announces Resignation of Zeenath Begum Binti Mohamed Mastan as Joint Company Secretary

What Sunzen Biotech Berhad's (KLSE:SUNZEN) 27% Share Price Gain Is Not Telling You

Sunzen Biotech Berhad Announces Appointment of Lee Yew Weng as Non Independent and Non Executive Member of Remuneration Committee

Sunzen Biotech Berhad Appoints Lee Yew Weng as Non Independent and Non Executive Member of Nomination Committee

Second quarter 2023 earnings released: EPS: RM0.001 (vs RM0.001 in 2Q 2022)

Sunzen Biotech Berhad Announces the Resignation of Dr. Fong Chan Seng as Independent and Non Executive Director, Member of Remuneration Committee, Chairman of Nomination Committee

First quarter 2023 earnings released: EPS: RM0.002 (vs RM0.001 in 1Q 2022)

Sunzen Biotech Berhad Announces Redesignation of Ching Chee Pun as Executive Chairman

Full year 2022 earnings released: EPS: RM0.005 (vs RM0.001 in FY 2021)

Third quarter 2022 earnings released: EPS: RM0.001 (vs RM0 in 3Q 2021)

Second quarter 2022 earnings released: EPS: RM0.001 (vs RM0 in 2Q 2021)

First quarter 2022 earnings released: EPS: RM0.001 (vs RM0 in 1Q 2021)

Sunzen Biotech Berhad Announces Resignation of Lim Lee Kuan as Company Secretary

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Sunzen Biotech Berhad Announces the Re-Designation of Teo Yek Ming from Group Chief Executive Officer to Group Managing Director

Sunzen Biotech Berhad (KLSE:SUNZEN) completed the acquisition of Finsource Solution Sdn Bhd from Teo Yek Ming, Ching Chee Pun, Lee Ching Yong and Low Chee Yeap.

Health Check: How Prudently Does Sunzen Biotech Berhad (KLSE:SUNZEN) Use Debt?

Full year 2020 earnings released: RM0.025 loss per share (vs RM0.034 loss in FY 2019)

New 90-day high: RM0.22

Sunzen Biotech Berhad (KLSE:SUNZEN) entered into a conditional share sale agreement to acquire Finsource Solution Sdn Bhd from Teo Yek Ming, Ching Chee Pun, Lee Ching Yong and Low Chee Yeap for MYR 12.4 million.

New 90-day high: RM0.20

Is Sunzen Biotech Berhad (KLSE:SUNZEN) Weighed On By Its Debt Load?

Third quarter 2020 earnings released: RM0.001 loss per share

Sunzen Biotech Berhad Announces Re-Designation of Ching Chee Pun from Non-Independent Director to Executive Director

First half earnings released

New 90-day high - RM0.21

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd